Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM)’s share price shot up 12.2% on Monday . The company traded as high as $0.40 and last traded at $0.36. 631,743 shares changed hands during trading, a decline of 13% from the average session volume of 725,458 shares. The stock had previously closed at $0.41.
A number of brokerages have recently weighed in on ATNM. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday. B. Riley set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, March 14th. Finally, Zacks Investment Research upgraded Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Tuesday, January 16th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $3.75.
The firm has a market capitalization of $32.44, a P/E ratio of -0.77 and a beta of 40.64.
An institutional investor recently raised its position in Actinium Pharmaceuticals stock. D.A. Davidson & CO. grew its holdings in Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 157,000 shares of the biotechnology company’s stock after purchasing an additional 109,000 shares during the period. D.A. Davidson & CO. owned approximately 0.20% of Actinium Pharmaceuticals worth $104,000 as of its most recent SEC filing.
ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals (ATNM) Shares Up -12.2%” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.thestockobserver.com/2018/03/21/actinium-pharmaceuticals-atnm-shares-up-12-2.html.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.